Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of glioblastoma.
Adaptin Bio has obtained IND clearance from the FDA for APTN-101 in glioblastoma, enabling initiation of a first-in-human phase I trial in patients diagnosed with WHO grade IV malignant glioma.
Tumor protein p73 (TP73) has been commonly tagged as a putative tumor suppressor, but it may positively regulate the growth and stemness of cancer stem cells.
Diakonos Oncology Corp. has developed a process to manufacture dendritic cell vaccines that the company believes are substantially more potent than its predecessors.
Kazia Therapeutics Ltd.'s stock shot up 248% on July 10 after the Sydney-based company reported that paxalisib showed a 3.8-month improvement in overall survival, a 33% improvement, for newly diagnosed unmethylated patients with glioblastoma (GBM) compared to the concurrent standard-of-care arm in the pivotal GBM-Agile phase II/III study.
Chicken ovalbumin upstream promoter transcription factor 2 (COUP-TFII, aka NR2F2) is dysregulated in different cancer types. However, its exact role remains controversial because it acts as an oncosuppressor in some tumors and as an oncogene in others. In glioma progression, the role of COUP-TFII is still unclear.
Kazia Therapeutics Ltd.'s stock shot up 248% on July 10 after the Sydney-based company reported that paxalisib showed a 3.8-month improvement in overall survival, a 33% improvement, for newly diagnosed unmethylated patients with glioblastoma (GBM) compared to the concurrent standard-of-care arm in the pivotal GBM-Agile phase II/III study.
